cagrilintide benefits Three new #obesity drugs—high-dose semaglutide, semaglutide plus cagrilintide, and oral orforglipron—may soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Cagrilintide is an amylin analogue
Description
Alternatives Enanthate: Similar to cypionate, slightly shorter half-life
For the first 14 weeks of the study, participants received cagrilintide and semaglutide as 2 separate injections in the stomach area
Smith, MD: Director of Education and Spokesperson for Life Extension
Put me down for interested and curious but skeptical
Key finding: AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial
